Works in PharmacoEconomics, 2025, Vol 43, Issue 1

Results: 9

How Much Better is Faster? Empirical Tests of QALY Assumptions in Health-Outcome Sequences: Tests of Health-Outcome Sequences: F. R. Johnson et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 1, p. 45, doi. 10.1007/s40273-024-01437-0

By:

Johnson, F. Reed;
Sheehan, John J.;
Ozdemir, Semra;
Wallace, Matthew;
Yang, Jui-Chen

Publication type:

Article

Acknowledgement to Referees: Acknowledgement to Referees: Acknowledgement to Referees.

Published in:: PharmacoEconomics, 2025, v. 43, n. 1, p. 1, doi. 10.1007/s40273-024-01464-x
Publication type:: Article

Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation: Universal Health Coverage of Opioid Agonist Treatment in Norway: P. Chaudhary et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 1, p. 93, doi. 10.1007/s40273-024-01442-3

By:

Chaudhary, Prayash;
Fadnes, Lars Thore;
Fosse, Steinar;
Chalabianloo, Fatemeh;
Johansson, Kjell Arne

Publication type:

Article

Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach: Incremental Cost per QALY of the Spanish NHS: L. Vallejo-Torres et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 1, p. 109, doi. 10.1007/s40273-024-01441-4

By:

Vallejo-Torres, Laura

Publication type:

Article

Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy: Traditional Versus Pharmacometric Pharmacoeconomic Models for Cost-Utility Analysis of Sunitinib: M. Centanni et al

Published in:

PharmacoEconomics, 2025, v. 43, n. 1, p. 31, doi. 10.1007/s40273-024-01438-z

By:

Centanni, Maddalena;
Nijhuis, Janine;
Karlsson, Mats O.;
Friberg, Lena E.

Publication type:

Article

The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis: A DCEA of Tocilizumab Coverage for Inpatients with COVID-19 and the Health Equity Impact in the USA: S. Kowal, K. L. Rosettie

Published in:

PharmacoEconomics, 2025, v. 43, n. 1, p. 67, doi. 10.1007/s40273-024-01436-1

By:

Kowal, Stacey;
Rosettie, Katherine L.

Publication type:

Article

Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification: Design and Features of Pricing and Payment Schemes for Health Technologies: V. Ardito et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 1, p. 5, doi. 10.1007/s40273-024-01435-2

By:

Ardito, Vittoria;
Ciani, Oriana;
Drummond, Michael

Publication type:

Article

Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability: Framework and Calculation Tool to Determine the Suitability of MEAs: M.H.E. Callenbach et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 1, p. 53, doi. 10.1007/s40273-024-01433-4

By:

Callenbach, Marcelien H. E.;
Vreman, Rick A.;
Leopold, Christine;
Mantel-Teeuwisse, Aukje K.;
Goettsch, Wim G.

Publication type:

Article

Economic Burden Associated with Pulmonary Arterial Hypertension in the United States: Economic Burden Associated With Pulmonary Arterial Hypertension in the United States: A. Watzker et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 1, p. 83, doi. 10.1007/s40273-024-01427-2

By:

Watzker, Anna;
Alsumali, Adnan;
Ferro, Christine;
Dieguez, Gabriela;
Park, Clare;
Lautsch, Dominik;
El-Kersh, Karim

Publication type:

Article